Fat Loss Peptide Stacks: Retatrutide + Tesamorelin Research Protocol
Retatrutide and Tesamorelin target fat loss through entirely different mechanisms — one drives systemic caloric reduction, the other targets visceral fat through growth hormone. Here's how researchers are combining them.
Peptide stacking — combining two or more compounds with complementary mechanisms — is a common research strategy when single-compound protocols plateau. For metabolic and fat loss research, Retatrutide and Tesamorelin represent one of the most mechanistically distinct pairings available.
Why These Two Compounds
Retatrutide and Tesamorelin are often discussed in the same breath because both reduce body fat. The comparison ends there — their mechanisms are almost entirely non-overlapping, which is exactly what makes them interesting to combine.
Retatrutide is a triple GLP-1/GIP/glucagon agonist. It reduces fat mass primarily by suppressing appetite and slowing gastric emptying (via GLP-1/GIP), while the glucagon component drives energy expenditure and hepatic fat oxidation. It works on whole-body energy balance.
Tesamorelin is a GHRH analogue. It stimulates endogenous growth hormone release, which in turn drives IGF-1-mediated lipolysis — specifically in visceral adipose tissue. It does not suppress appetite and has no direct effect on caloric intake.
Mechanism Comparison
| Mechanism | Retatrutide | Tesamorelin |
|-----------|-------------|-------------|
| Appetite suppression | Yes (GLP-1/GIP) | No |
| Visceral fat reduction | Yes (systemic) | Yes (primary mechanism) |
| Growth hormone axis | No | Yes (GHRH agonism) |
| Energy expenditure | Yes (glucagon) | Indirect (via GH/IGF-1) |
| Insulin sensitivity | Improves | Variable (GH can cause transient IR) |
What the Research Shows Individually
Retatrutide: Phase 2 TRIUMPH trial reported up to 24.2% total body weight reduction at 48 weeks at the highest dose — the largest reduction ever recorded in a pharmacological weight loss trial. Effects on visceral fat were proportional to total fat loss.
Tesamorelin: The DEFINE trials (Phase 3, FDA approval basis) showed ~15–18% reduction in visceral adipose tissue area in HIV-associated lipodystrophy patients over 26 weeks. Importantly, lean mass was preserved — a key differentiator from simple caloric restriction.
Stacking Rationale
The combination addresses:
- ·Total caloric intake — Retatrutide reduces it
- ·Energy expenditure — Retatrutide (glucagon) + Tesamorelin (GH axis) both contribute
- ·Visceral fat specificity — Tesamorelin provides this where Retatrutide's effect is more generalised
- ·Lean mass preservation — Tesamorelin's GH-driven IGF-1 is anabolic to muscle tissue, partially offsetting any lean mass loss from caloric deficit
Research Protocols
Individual compound protocols are well-documented in the research literature. When studying combinations, researchers typically introduce one compound first to establish baseline response before adding the second.
Retatrutide: Research doses in trials ranged from 1 mg to 12 mg weekly subcutaneous injection. Phase 2 used a dose-escalation approach starting at lower doses to manage GI side effects.
Tesamorelin: Clinical research uses 2 mg subcutaneous injection daily, typically administered in the morning before food. The FDA-approved protocol for lipodystrophy uses this dose continuously.
Key Considerations for Researchers
- ·Retatrutide significantly reduces food intake — Tesamorelin's GH effects are more pronounced in a caloric deficit state, which may amplify lipolysis beyond what either produces alone
- ·GH stimulation can transiently increase fasting glucose; researchers monitoring metabolic markers should track this when combining with a GLP-1 agonist that itself improves insulin sensitivity
- ·Tesamorelin loses efficacy if discontinued — visceral fat returns toward baseline within weeks of stopping
- ·Retatrutide's half-life supports once-weekly dosing; Tesamorelin requires daily administration
Ordering and Availability
JA Performance stocks both Retatrutide and Tesamorelin as research compounds verified to 99%+ purity by independent third-party laboratory. Both are available for Canadian researchers with discreet express shipping.
For individual compound deep-dives, see the Retatrutide guide and the Tesamorelin guide. For dosing calculations, use the peptide dosing calculator.
Note: All compounds are sold strictly for in vitro and laboratory research purposes. Not for human consumption.